iStockAnalyst.com (Free subscription) | 10/02/2009
On September 30, Teva Pharmaceutical Industries Ltd (TEVA), sold the worldwide rights to a generic version of the white blood-cell boosting drug filgrastim to Hospira Inc (NYSE:HSP). [More...]
PXDCO Reviews (Free subscription) | 08/14/2009
Filed under: Michael Jackson We just got off the phone with Hospira Inc., one of the Propofol manufacturers mentioned in the Las Vegas warrant used to search a pharmacy connected to Dr. Conrad Murray.It appears law enforcement believes Hospira manufactured one of the bottles of … Permalink Bookmark It Hide Sites $$('div.d18494').each( function(e) { e.visualEffect('slide_up',{duration:0.5}) });...
TMZ (Free subscription) | 08/14/2009
Filed under: Michael Jackson We just got off the phone with Hospira Inc., one of the Propofol manufacturers mentioned in the Las Vegas warrant used to search a pharmacy connected to Dr. Conrad Murray.It appears law enforcement believes Hospira manufactured one of the bottles of ... Permalink
Chicago Tribune (Free subscription) | 07/29/2009
Hospira Inc., the Lake Forest-based maker of injectable drugs and hospital products, said second-quarter profits dropped more than 60 percent due to charges from a restructuring of certain operations worldwide.
Market Wire (Free subscription) | 07/08/2009
NEW DELHI, INDIA (MARKET WIRE) Analyst Choice has combined some of the best financial and technical minds worldwide to bring you an array of free quality equity research and reporting. Today we have begun in-depth reporting on our website evaluating the current market condition of Hospira Inc. (NYSE: HSP), Gap Inc. (NYSE: GPS), General Maritime Corporation (NYSE: GMR), Exelon Corporation (NYSE: EXC),...
Market Watch (Free subscription) | 06/19/2009
SAN FRANCISCO (MarketWatch) -- Generic drugs company Hospira Inc. said late Thursday it has won a federal court decision that its version of the Sanofi-Aventis SA chemotherapy medication Eloxatin does not infringe on the original. Hospira also said in a statement that it has won tentative Food and Drug Administration approval for its generic version of Eloxatin, which will be available in solution...
Medical News Today (Free subscription) | 05/27/2009
Hospira Inc. (NYSE: HSP) presented two posters at the World Congress of Nephrology reporting new data and analysis on epoetin zeta (Retacrit®), its biosimilar epoetin. Direct analysis of epoetin zeta and epoetin alfa drug product formulations was undertaken in order to provide further assessment of product quality1.
PR News Wire (Free subscription) | 05/14/2009
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve...
PR News Wire (Free subscription) | 05/07/2009
Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated formats, several of which are proprietary, such as its ADD-Vantage Drug Delivery System and iSecure(R) prefilled syringes. Therapeutic segments include anesthesia, anti-infectives,...
PR News Wire (Free subscription) | 05/07/2009
LAKE FOREST, Ill., May 7 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: ), a global specialty pharmaceutical and medication delivery company, today announced that the company will present at the Bank of America and Merrill Lynch 2009 Health Care Conference on Wednesday, May 13, 2009, in New York City.The presentation is scheduled to begin at 8:00 a.m. Eastern time on Wednesday, May 13, 2009. It will...
Business (Free subscription) | 05/07/2009
Australia’s biggest generic drug manufacturer says it will move future jobs to India because of uneconomical patent laws. US pharmaceutical company Hospira says while it isn’t sacking any of its exis
PR News Wire (Free subscription) | 05/05/2009
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve...
Rocky Mount Telegram - Business (Free subscription) | 04/30/2009
Legislation in Washington that is proposing to allow manufacturers to sell biogeneric drugs in the U...
Contract Pharma Breaking News (Free subscription) | 04/28/2009
Hospira 1Q09 1Q Revenues: $859.7 million (-3%) 1Q Earnings: $114.7 million (earnings were $65.4 million in 1Q08) Comments: Global Specialty Injectables revenue was down 7.5% to $429.7 million, with Europe, Middle East & Africa sales down 26% to $57.6 million and the Americas down 2% to $333.1 million. Other Global Pharma revenues were $169.1 million in the quarter (+4%). Growth in Other Pharma...
Chicago Tribune (Free subscription) | 04/28/2009
Otherwise slow growth for the hospital products maker Hospira Inc. said this morning first-quarter net income jumped 153 percent thanks largely to a settlement with the Internal Revenue Service following a routine audit, boosting otherwise slow growth for the hospital products maker.
Videos